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Interferon-γ signaling is associated with BRCA1 loss-of-
function mutations in high grade serous ovarian cancer
Horacio Cardenas1,11, Guanglong Jiang2,3,11, Jessica Thomes Pepin4,11, J. Brandon Parker1, Salvatore Condello1,
Kenneth P. Nephew4,5,6,7, Harikrishna Nakshatri 5,8, Debabrata Chakravarti1,9, Yunlong Liu2,5 and Daniela Matei1,9,10*
Loss-of-function mutations of the breast cancer type 1 susceptibility protein (BRCA1) are associated with breast (BC) and ovarian
cancer (OC). To identify gene signatures regulated by epigenetic mechanisms in OC cells carrying BRCA1 mutations, we assessed
cellular responses to epigenome modifiers and performed genome-wide RNA- and chromatin immunoprecipitation-sequencing in
isogenic OC cells UWB1.289 (carrying a BRCA1 mutation, BRCA1-null) and UWB1.289 transduced with wild-type BRCA1 (BRCA1+).
Increased sensitivity to histone deacetylase inhibitors (HDACi) was observed in BRCA1-null vs. BRCA1+ cells. Gene expression
profiles of BRCA1-null vs. BRCA1+ cells and treated with HDACi were integrated with chromatin mapping of histone H3 lysine 9 or
27 acetylation. Gene networks activated in BRCA1-null vs. BRCA1+OC cells related to cellular movement, cellular development,
cellular growth and proliferation, and activated upstream regulators included TGFβ1, TNF, and IFN-γ. The IFN-γ pathway was altered
by HDACi in BRCA1+ vs. BRCA1-null cells, and in BRCA1-mutated/or low vs. BRCA1-normal OC tumors profiled in the TCGA. Key IFN-
γ-induced genes upregulated at baseline in BRCA1-null vs. BRCA1+OC and BC cells included CXCL10, CXCL11, and IFI16. Increased
localization of STAT1 in the promoters of these genes occurred in BRCA1-null OC cells, resulting in diminished responses to IFN-γ or
to STAT1 knockdown. The IFN-γ signature was associated with improved survival among OC patients profiled in the TCGA. In all, our
results support that changes affecting IFN-γ responses are associated with inactivating BRCA1 mutations in OC. This signature may
contribute to altered responses to anti-tumor immunity in BRCA1-mutated cells or tumors.
npj Precision Oncology            (2019) 3:32 ; https://doi.org/10.1038/s41698-019-0103-4
INTRODUCTION
Genetic or epigenetic inactivation of several tumor suppressor
genes (TSGs), including TP53, PTEN, BRCA1, BRCA2, DOK2, RB1, and
others1–3, are strongly associated with tumor initiation and
progression of ovarian and breast cancers. The most commonly
mutated TSG associated with hereditary OC, BRCA1, has been
implicated in the initiation of events leading to transformation of
the ovarian/fallopian tube epithelium.4,5 Inactivating BRCA1
mutations occur in approximately 5–10% of all high-grade serous
ovarian cancers (HGSOC) and account for more than half of the
inherited syndromes associated with OC.6 Additionally, epigenetic
silencing of BRCA1 through promoter CpG island methylation
occurs in approximately 20% of HGSOC,1,7 and has been linked to
OC progression. The BRCA1 protein has four domains: the zinc-
finger C3HC4 RING domain involved in protein ubiquitination, the
BRCA1 serine (SCD) domain which contains phosphorylation sites
responsible for localization of the protein to DNA damage sites,
and two C-terminal (BRCT) domains that regulate DNA repair
responses.8,9 Through its interaction with partner proteins, BRCA1
is part of the complex that repairs DNA double-strand breaks
(DSB) and maintains the integrity of the genome.10,11 Tumor-
associated BRCA1 mutations commonly affecting the BRCT
domain confer increased sensitivity to DNA damaging agents
and to poly ADP ribose polymerase (PARP) inhibitors and are
associated with substantial transcriptional rewiring in cancer cells
and tumors.12–15
Acetylation of histone H3 lysine residues at positions 9- and
27-marks active promoters and enhancers and is regulated by the
concerted activities of histone acetyl transferases (HATs) and
histone deacetylases (HDACs).16 Recent reports indicated that
treatment with HDAC inhibitors of ovarian and breast cancer cells
induce “BRCA-ness” features associated with increased response
to DNA damage and PARP inhibitors.17,18 It had also been
reported that the BRCT domain of BRCA1 interacts with histone
deacetylases (HDAC) 1 and 2 and with other components of the
chromatin remodeling complex19, supporting a potential associa-
tion between presence of BRCA1 mutations and reorganization of
histone marks delineating active regions of chromatin. Therefore,
we sought to determine the transcriptomic signatures induced by
HDAC inhibitors in BRCA1 mutated or in BRCA1-wild-type OC cells
and their association with genome-wide distribution of H3
acetylation marks, thus defining differences in transcription-
ready chromatin regions between cells harboring BRCA1 muta-
tions versus wild type.
Here we compared the transcriptome of OC cells carrying a loss
of function BRCA1 mutation and cells in which BRCA1 was
restored at baseline and in response to treatment with an HDAC
inhibitor. These analyses integrated with gene expression profiles
of BRCA1-deficient (mutated BRCA1 or expression levels below the
tenth quantile) or BRCA1-normal (not mutated BRCA1 and
expression level above the first quartile) HGSOC tumors profiled
in The Cancer Genome Atlas (TCGA) project1 pointed to an IFN-γ
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signature being hyper-active at baseline in BRCA1-mutated cancer
cells. IFN-γ is secreted by natural killer, helper, and cytotoxic T
lymphocytes and is involved in innate and adaptive immunity.
Cellular signaling induced by the cytokine involves binding to its
receptors (IFNGR1 and 2) and activation of the Janus kinase
JAK–STAT pathway. Upon phosphorylation of Ser-727, STAT1
dimerizes and its homodimers translocate to the nucleus, localize
to target gene promoters inducing transcription.20 IFN-γ has been
recognized as a key player in anti-tumor immune responses.21 The
cytokine induces cancer cell apoptosis and growth arrest22–24 and
its secretion by activated CD8 cytotoxic T cells in the tumor milieu
is responsible for T cell-induced anti-tumor effects. We showed
that the IFN-γ signature in BRCA1-mutated cells and tumors carries
prognostic significance in HGSOC, is associated with distinct
patterns of H3K9 and H3K27 acetylation, and is functionally linked
to partial resistance to IFN-γ stimulation. Our findings suggest a
potential mechanism by which loss of function BRCA1 mutations
could alter the response of cancer cells to external stimuli.
RESULTS
Differential response to HDAC inhibitors based on the presence of
a mutated BRCA1
Based on recent reports suggesting synergy between epigenome-
targeting agents and PARP inhibitors,25 with HDAC inhibitors
inducing a BRCA-ness state,17,26 we tested differential growth
responses of isogenic cancer cells carrying or not a BRCA1
mutation to epigenome-modifying agents. We utilized the
isogenic cells UWB1.289 and UWB1.289 transduced with BRCA1
(ref. 27) (hereafter referred to as BRCA1-null and BRCA1+, per
ATCC nomenclature, respectively). The UWB1.289 cells carry a
2594delC mutation which introduces a stop at codon 845 leading
to a truncated protein lacking a large portion of the carboxyl
terminus. The deleted portion includes the SCD and the two BRCT
domains. Consistent with a previous report,27 non-mutated BRCA1
mRNA and protein levels were very low, and H2AX phosphoryla-
tion (γH2AX) in response to DNA damage induced by etoposide
was increased in BRCA1-null compared with BRCA1+ cells
(Supplementary Fig. 1).
We observed no differences in cell survival after treatment with
either a DNA methyltransferase inhibitor (guadecitabine; Supple-
mentary Fig. 2a) or an inhibitor of the polycomb repressive
complex 2 enzymatic component EZH2 (GSK126; Supplementary
Fig. 2b) between OC cells carrying a deleterious BRCA1 mutation
and those with functional BRCA1. However, BRCA1-null cells were
more sensitive than BRCA1+ cells to the HDAC inhibitor entinostat
(Fig. 1a; IC50 of 3.0 μM vs. 6 μM), suggesting potential baseline
differences in histone protein acetylation between the two cell
lines. Total HDAC activity and HDAC1 expression levels were also
slightly decreased in BRCA1-null vs. BRCA1+ cells (Supplementary
Fig. 3a, b), while H3K9ac and H3K27ac basal levels were modestly
increased in BRCA1-null vs. BRCA1+ cells (Supplementary Fig. 3c,
d). Consistent with its known HDAC inhibitory activity, entinostat
induced H3K9 and H3K27 acetylation relative to H3 levels in both
cell lines (Fig. 1b, c).
Transcriptomic changes associated with mutated BRCA1 and
response to an HDAC inhibitor
We next examined changes in gene expression after HDACi
treatment. Entinostat, an HDAC1 and HDAC3 inhibitor, was used at
0.5 μM (non-toxic concentration). Unsupervised hierarchical clus-
tering (Fig. 1d–f) and principal component analysis (PCA,
Supplementary Fig. 4) demonstrated differences in gene expres-
sion associated with BRCA1 deficiency (Fig. 1d) and in response to
entinostat in BRCA1+ (Fig. 1e) and BRCA1-null (Fig. 1f) cells.
Absence of a functional BRCA1 was associated with changes in
expression (P < 0.01, t-test, FDR < 0.05) of more than 6000 genes
(BRCA1-null vs. BRCA1+, Fig. 1g). BRCA1 deficiency also altered
the response to entinostat; 1738 and 638 genes whose expression
was changed by entinostat were unique to BRCA1+ or BRCA1-null
cells, respectively, while expression of 1274 genes changed in
response to the HDACi in both cell lines (Fig. 1h, Supplementary
Tables 3–5).
Distinct gene expression profiles associated with BRCA1
expression levels and mutational status in HGSOC
To determine whether the genomic changes observed between
BRCA1 mutant and WT cells correlate with molecular profiles of
human tumors, we analyzed gene expression measured by Agilent
G4502A microarrays in HGSOC tumors from the TCGA1 program.
These tumors were grouped based on BRCA1 expression levels
into BRCA1-deficient (56 tumors, BRCA1 expression <10th
quantile) or mutated (19 tumors) and BRCA1-normal (330 tumors,
BRCA1 expression >25th quantile), as described in Fig. 2a.
Expression levels of 3541 genes differed significantly (P < 0.01, t-
test, FDR < 0.05) between BRCA1-deficient or mutated and BRCA1-
normal tumors (Fig. 2b, volcano plot), indicating that the
expression and function of BRCA1, directly or indirectly, induce
changes in the transcriptome of HGSOC. Additionally, 1117 genes
were differentially expressed both in BRCA1-null vs. BRCA1+ OC
cells and in the BRCA1-deficient vs. BRCA1-normal ovarian tumors
(Fig. 2c), supporting similarity between the selected cellular model
to study BRCA1 mutation-associated transcriptomic changes and
human HGSOC tumors.
BRCA1 deficiency was associated with changes in gene networks
regulated by entinostat in OC cells and tumors
To gain further insight into the functional implications of
transcriptomic differences in BRCA1-mutated cells and tumors,
we performed Ingenuity Pathway Analysis (IPA, Supplementary
Tables 6 and 7) and compared the “Top Molecular and Cellular
Functions” (Table 1) and the “Top Upstream Regulators” (Table 2)
enriched in BRCA1-null/deficient vs. BRCA1+ cells and tumors.
Two functions (cell-to-cell signaling and interaction, and cellular
growth and proliferation, and two upstream regulators (TGFB1
and IFNG) were shared between differentially expressed genes in
the isogenic cell lines and differentially expressed genes in BRCA1-
deficient vs. normal ovarian tumors. Comparison of upstream
regulators activated or inhibited in the analysis comparing BRCA1-
null vs. BRCA1+ cells, entinostat-treated BRCA1+, and entinostat-
treated BRCA-null cells showed changes induced by entinostat in
the activation Z-score of several upstream regulators (e.g. IFNG,
TNF, NF-kB, IL1A, TGFB1, and others; Fig. 2d). IFNG was detected as
activated (Z-score 6.7) in BRCA1-null relative to BRCA1+ cells, and
also in entinostat-treated BRCA1+ vs. BRCA1+ (Z-score 4.0), but
not in entinostat-treated BRCA-null vs. BRCA1-null cells (Z-score <
2). This suggested that activation of the IFNG pathway could be
induced by HDAC inhibition in BRCA1+ cells to levels similar to
those observed in BRCA1-null cells, and that this effect requires
the presence of a functional BRCA1. Other upstream regulators
such as TNF and TGFB1 were activated by entinostat regardless of
BRCA1 status. These integrated analyses indicated that the IFNG
pathway in particular was influenced by BRCA1 loss of function
and was altered in response to HDACi in OC cells and tumors
expressing functional BRCA1.
Activation of IFN-γ pathway in BRCA1-null vs. BRCA1+ cells
We next verified whether the IFNG pathway was indeed activated
in BRCA1-null vs. BRCA1+ cells. IFI44, IRF9, IL1A, OAS2, and OAS3
were identified among 17 IFN-γ-regulated genes classified by IPA
as been activated (Supplementary Table 8). To validate activation
of the IFN-γ pathway in the presence of a BRCA1 mutation, we
measured basal and IFN-γ-induced expression of several target
H. Cardenas et al.
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genes in BRCA1-null cells (stably transfected with the vector
pcDNA3.1) and in BRCA1+ UWB1.289 OC cells. Among the key
target genes, the inflammatory chemokines encoded by CXCL10
(C-X-C motif chemokine 10) and CXCL11 (C-X-C motif chemokine
11) promote T cell chemotaxis and play a role in anti-tumor
immunity.28 IFI16 (interferon gamma inducible protein 16) is an
innate sensor for intracellular DNA that triggers a pro-
inflammatory and growth inhibitory response through activation
of IFN-β and NF-κB pathways.29–31 Basal levels of CXCL10 (~20-
fold), CXCL11 (~15-fold), and IFI16 (~160-fold) were significantly
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upregulated in BRCA1-null (+vector) vs. BRCA1+ OC cells (Fig. 3a).
IFN-γ induced a more robust phosphorylation of STAT1 in BRCA1-
null (+vector) cells compared to BRCA1+ cells (Fig. 3b,
Supplementary Fig. 5a); however, induced expression of CXCL10
and IFI16 (Fig. 3c) was less in BRCA1-null (+vector) vs. BRCA1+
cells, probably because baseline levels of these transcripts were
already significantly increased in BRCA1-null cells. In contrast,
differences in responses to IFN-α were less pronounced. Baseline
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Fig. 2 Gene expression profiles associated with BRCA1 expression levels in ovarian cancer (OC) tumors. a Distribution of BRCA1 mRNA
expression levels in high-grade serous ovarian cancer (HGSOC) specimens from the TCGA dataset. The upper 25% quantile (blue line to the
right) were considered BRCA1-normal while the low 10% quantile (red line to the left) were considered BRCA1-deficient. b Volcano plot of
differentially expressed genes between BRCA1-deficient and BRCA1-normal HGSOC tumors in the TCGA database. c Venn diagram shows the
numbers of specific or shared genes differentially expressed between BRCA1-deficient and BRCA1-normal OC tumors (TCGA) and between
BRCA1-null and BRCA1+ UWB1.289 OC cells. d IPA comparative analysis shows activation Z-scores of differentially expressed upstream
regulators in BRCA1-null relative to BRCA1+ UWB1.289 OC cells, and in the same cell lines in response to entinostat treatment (0.5 μM for 24 h,
n= 2).
Fig. 1 Gene expression changes associated with BRCA1 mutation in ovarian cancer (OC) cells. a Survival (means ± s.e.m., n= 4) measured by
the CCK8 assay of UWB1.289 OC cells (BRCA1-null) and UWB1.289 cells transfected with BRCA1 (BRCA1+) and treated with entinostat for 72 h.
*P < 0.05 (t-test). b, c Western blot and densitometric analysis (means ± s.e.m., n= 3) of entinostat effects (72 h treatment) on H3K9ac b and
H3K27ac c levels in BRCA1-null and BRCA1+ UWB1.289 OC cells. *P < 0.05 (t-test) relative to 0 entinostat. M, protein markers. d–f Unsupervised
hierarchical clustering of differentially expressed genes measured by RNAseq between BRCA1-null and BRCA1+ d, entinostat-treated BRCA1+
compared with BRCA1+ e, and entinostat-treated BRCA1-null compared with BRCA1-null f UWB1.289 OC cells. Colored horizontal lines
represent genes and columns represent specimens analyzed. Cells were treated with 0.5 μM entinostat for 24 h (n= 2). g Numbers of
differentially expressed genes in BRCA1-null relative to BRCA1+UWB1.289 OC cells treated with 0.5 μM entinostat for 24 h (n= 2). h A Venn
diagram shows numbers of common and unique differentially expressed genes determined by RNAseq in BRCA1+ and BRCA1-null UWB1.289
OC cells treated with 0.5 μM entinostat (Ent) for 24 h (n= 2).
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expression levels of IFITM1 and MX1, known IFN-α targets,21 were
also increased in BRCA1-null (+vector) compared to BRCA1+ cells,
but to a lesser extent than IFN-γ-regulated genes (Fig. 3d), while
the IFN pathway inhibitor suppressor of cytokine signaling 2
(SOCS2) was downregulated in BRCA1-null cells (not shown),
perhaps contributing to activation of the IFN pathway in this
context. Response to IFN-α stimulation was similar in the two cell
lines as measured by STAT1 phosphorylation at Tyr701 (Fig. 3e,
Supplementary Fig. 5b) and target gene induction (Fig. 3f),
although no differences in basal STAT1 phosphorylation were
detected between the cell lines.
To understand the mechanism causing activated basal IFN-γ
signaling in BRCA1-null cells, we assessed the recruitment of the
transcription factor STAT1 to the promoters of target genes
CXCL10, CXCL11, and IFI16 by using chromatin immunoprecipita-
tion (ChIP). Increased STAT1 localization in regions containing the
predicted STAT1-binding sites (GAS elements) within the promo-
ters of CXCL10, CXCL11, and IFIT16 was observed in BRCA1-null vs.
BRCA1+ cells (Fig. 3g), in the absence of ligand. These data
support the concept that the pathway is activated under basal
conditions in cells carrying a BRCA1 mutation.
To exclude the possibility that these observations were cell
model dependent, we tested the response to IFN in isogenic
BRCA1 mutated breast cancer cells (HCC1937) and cells stably
transfected with BRCA1 (HCC1937+ BRCA1). BRCA1 protein was
absent in HCC1937 compared to HCC1937+ BRCA1 cells, con-
sistent with their known phenotype32 (Supplementary Fig. 5c).
IFN-γ-induced expression of CXCL10, CXCL11, IFI16 (Fig. 4a), MX1,
and IFITM1 (Supplementary Fig. 5d) was abrogated in BRCA1-
mutated HCC1937 cells compared with HCC1937+ BRCA1 cells to
an even greater extent than observed levels in OC cells. To verify
the increased activation levels of the IFN-γ pathway associated to
BRCA1 mutations, we measured expression of IFN-γ-regulated
genes in other cellular models and tumors. Expression of CXCL10
and CXCL11 was increased in BRCA1 mutated vs. BRCA1-normal
mammary immortalized cells lines, as measured by qRT-PCR (Fig.
4b), and in BRCA1-deficient relative to BRCA1-normal OC tumors
from TCGA (Supplementary Fig. 6a). Together, these data support
that BRCA1-mutated cells display elevated IFN-γ activation and
respond less efficiently to IFN-γ than cells harboring a functional
BRCA1.
BRCA1 mutational status alters cellular responses to IFN-γ
We next determined the cellular responses to IFNs in isogenic
BRCA1+/− cells. IFN-γ decreased (P < 0.05, t-test) the survival of
both cell types, with increased cytotoxic effects in BRCA1+ vs.
BRCA1-null cells in both OC and BC cell models (Fig. 4c, d). In
contrast, IFN-α had modest effects on the survival of BRCA1-null or
BRCA1+ OC cells, even at concentrations of 1 μg/mL (Fig. 4e, f).
Furthermore, shRNA mediated stable knock down of STAT1 (Fig.
4g), the main transcription factor mediating IFN-γ signaling,
significantly suppressed the proliferation of BRCA1+ cells, but did
not impact BRCA1-null OC cells (Fig. 4h), supporting that cells
carrying a BRCA1 mutation were less susceptible to IFN-γ-
mediated cytotoxicity. Expression levels of IFI16 were down-
regulated by STAT1 knock down in BRCA1+, but not in BRCA1-null
cells, suggesting less responsiveness to this pathway manipulation
in cells harboring deleterious BRCA1; however, the other two IFNγ
targets (CXCL10 and CXCL11) were not consistently altered by
STAT1 knock down (Supplementary Fig. 6b).
Having observed activation of the IFNG pathway in response to
entinostat in our RNA-sequencing analyses in cells with functional
BRCA1 (Fig. 2d) and based on previous observations suggesting
cooperation between STAT1 and HDAC1 in transcription regula-
tion,33 we investigated responses to IFNs in the presence of an
HDACi in BRCA1-null vs. + cells. Interestingly, the response to IFN-
γ (CXCL10, CXCL11, and IFI16 mRNA expression) was augmented by
entinostat in BRCA1+, but BRCA1-null cells remained resistant to
IFN-γ, even after treatment with HDACi (Fig. 4i), supporting that
regulation of IFN-γ responses is influenced by BRCA1 and histone
Table 1. Top molecular and cellular functions identified by IPA among genes differing in expression (RNAseq, left) between BRCA1-null and BRCA1+
ovarian cancer (OC) cells, and among differentially expressed genes between BRCA1-deficient and BRCA1-normal OC tumors from the TCGA
database (right).
BRCA1-null vs. BRCA1+ OC cells BRCA1-deficient vs. BRCA1-normal OC tumors, TCGA
Molecular and cellular functions P value Number of molecules Molecular and cellular functions P value Number of molecules
Cellular movement 5.3E-10–1.6E-53 702 Cellular growth and proliferation 1.6E-03–2.1E-11 975
Cellular development 5.1E-10–4.8E-37 995 Cell death and survival 2.6E-03–1.1E-09 966
Cellular growth and proliferation 5.1E-10–8.4E-31 1057 Cellular function and
maintenance
2.5E-03–5.1E-07 770
Cell morphology 5.1E-10–1.7E-30 721 Cell-to-cell signaling and
interaction
2.6E-03–9.7E-07 324
Cell-to-cell signaling and
interaction
3.7E-10–4.8E-30 588 Molecular transport 2.4E-03–1.1E-06 574
Table 2. Top upstream regulators determined by IPA among genes
differing in expression between BRCA1-null and BRCA1+ OC cells
(left), and among differentially expressed genes between BRCA1-
deficient and BRCA1-normal OC tumors from the TCGA database
(right).
BRCA1-null vs. BRCA1+ ovarian cancer cells BRCA1-deficient vs.
BRCA1-normal ovarian
cancer tumors, TCGA
Top upstream
regulator
P value of
overlap
Predicted
activation
Top upstream
regulator
P value of
overlap
TNF 2.1E-61 Activated HNF4A 7.4E-19
TGFB1 3.3E-51 Activated TP53 1.8E-10
IFNG 1.4E-36 Activated TGFB1 1.4E-09
β-Estradiol 1.8E-35 FAS 7.8E-08
SMARCA4 2.2E-33 Activated ESR1 5.9E-07
IL1B 2.6E-33 Activated Interferon
beta-1a
1.7E-06
Progesterone 2.2E-27 IFNG 4.6E-06
Estrogen
receptor
2.1E-24 Inhibited OSM 4.7E-06
SP1 1.6E-23 Activated FOXO1 6.9E-06
VEGF 9.0E-23 Activated IL27 1.6E-05
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CXCL11, and IFI16 measured by ChIP in BRCA1+ and BRCA1-null UWB1.289 OC cells. *P < 0.05 (t-test); F1 forward primer; R1 reverse primer.
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deacetylation. Addition of either IFN-α or IFN-γ (10 ng/mL) to
entinostat did not increase cytotoxicity in BRCA1+ cells (Supple-
mentary Fig. 7a), but both IFNs potentiated the cytotoxic effects
induced by entinostat in BRCA1-null OC cells (Supplementary Fig.
7b). The effects of entinostat on key genes involved in IFNγ
signaling in BRCA1-null and BRCA1+ cells, as measured by RNA-
sequencing, are summarized in Supplementary Table 9. Collec-
tively these data support that HDAC inhibition alters the cellular
responses to IFNs and that these effects depend on
functional BRCA1.
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Genome-wide histone H3 acetylation differs in BRCA1-null and
BRCA1+ cells
Based on the observed differences in response to HDACi, we
examined differential H3K9 and H3K27 acetylated chromatin
marks (basal state) between BRCA1-null and BRCA1+ cells. ChIP-
seq analysis identified more than 100,000 peaks corresponding to
H3K9ac or H3K27ac marks in the genome, with nearly half of them
located in introns (Fig. 5a, b). More H3K9ac and H3K27ac marks
(2973 and 3336, respectively) were identified in BRCA1-null than in
BRCA1+ cells (Fig. 5a) corroborating greater H3K9 and H3K27
acetylation levels in the absence of BRCA1 measured by western
blotting (Supplementary Fig. 3c, d). A total of 11,691 H3K9ac and
20,976 H3K27ac marks differed between BRCA1-null vs. BRCA1+
cells, approximately half of them located in introns, 30% in
intergenic, and the remaining in promoters, exons, and TSS
genomic regions (Fig. 5c). Clustering of differential H3K27ac peaks,
which are usually associated with enhancers and promoters,
showed increased acetylation within two clusters in BRCA1-null
cells but not in the other clusters (Fig. 5d). We identified 325 gene
promoters differentially marked with H3K9ac and 415 with
H3K27ac, which were associated with differential gene expression
(RNA-seq) in BRCA1-null vs. BRCA1+ cells (Fig. 5e); and among
them, we detected the IFN-γ-regulated gene IFI16 (Fig. 5f).
Increased deposition of H3K9ac in the promoter region of IFI16
in RBCA1-null vs. BRCA1+ UWB1.289 OC cells was also verified by
real-time PCR on chromatin immunoprecipitated with H3K9ac
antibody (Fig. 5g, Supplementary Fig. 8). These data support the
notion that IFN-γ signaling in the BRCA1-null OC cells is associated
with distinct deposition of H3K9 and H3K27 acetylated marks.
IFN-γ signature in HGSOC
To assess the significance of the IFN-γ pathway in human tumors,
we used regression analysis and measured the association
between mRNA levels of IFN-γ and CXCL10, CXCL11, or IFI16 in
HGSOC tumors from the TCGA database. Statistically significant
associations between IFN-γ and each of the three genes were
observed, supporting that CXCL10, CXCL11, and IFI16 are inducible
by IFN-γ in HGSOC (Fig. 6a). Additionally, the mRNA expression
levels of CXCL10, or CXCL11 with IFI16 were highly positively
correlated (P < 1 × 10−15, Fig. 6b), and separated the tumors in two
distinct subgroups, as shown by hierarchical clustering (Fig. 6c). To
determine whether the IFN-γ signature carried prognostic value,
OC samples were classified as “high expressing” subgroup, if the
expression of the three genes was higher than their correspond-
ing median values or as “low expressing” subgroup, if the
expression level for all three genes was lower than the median
value. Seventy-three and 84 ovarian tumors were thus classified as
“high” and “low” subgroups and a trend towards prolonged
overall survival recorded for the IFN-γ “high” vs. “low” subgroups
(Fig. 6d, P= 0.052, Cox proportional hazard regression). Taken
together, the data support the clinical significance of IFN-γ and the
potential loss of sensitivity to IFN-γ in BRCA1-null tumors due to a
baseline augmented status.
Lastly, given the significance of the IFN-γ pathway to anti-tumor
immune responses and to determine whether BRCA1-deficient
and normal tumors differed in type of immune cell infiltrates, we
used TIMER to predict the relative numbers of immune cells in
tumor specimens based on gene expression data.34 Predicted
numbers of six immune cell subtypes (B cells, CD4, CD8,
macrophages, neutrophils, and dendritic cells) are shown in
Supplementary Fig. 9. Significant differences in neutrophils (P=
0.001, t-test) and dendritic cells (P= 0.01, t-test) infiltration were
estimated based on the transcriptomic signature for BRCA1-
deficient vs. normal ovarian tumors, but no differences were
detectable for the other immune cell types.
DISCUSSION
Consistent with previous reports,14,15 our findings support that
BRCA1 mutations are associated with significant transcriptomic
changes in OC cells and tumors. BRCA1 has been implicated in
transcriptional regulation through several mechanisms including
direct interactions with the p300/CBP activator complex35 and
maintenance of the heterochromatin structure through ubiquity-
lation of histone H2A.36 Here we show that some of these changes
are associated with distinct patterns of chromatin-associated H3K9
and H3K27 acetylated marks, leading to differences in cellular
responses to HDACi and to an IFN-γ gene signature detectable in
BRCA1-mutated cancer cells. This signature was also validated in
the gene expression profiles of ovarian carcinomas profiled by the
TCGA.1 Our results have several implications.
First, we observed differences in cell proliferation in response to
treatment with HDACi in cells carrying a BRCA1 loss of function
mutation vs. cells expressing functional BRCA1. Interestingly,
HDACi have been recently shown to downregulate expression of
genes involved in DNA damage response (RAD51 and BRCA1)17
and to sensitize homologous recombination proficient cells to
DNA damage-inducing agents. It is therefore possible that the
increased cytotoxicity of entinostat observed in BRCA1 mutated
cancer cells was caused by the impairment in the DNA damage
response in addition to the homologous recombination deficiency
caused by BRCA1 loss of function. However, the mechanism by
which genes involved in DNA repair are downregulated by HDACi
remains not clear.
Here we show distinct transcriptomic profiles corresponding to
distinct mapping of H3K9ac and H3K27ac depending on the
presence of a functional BRCA1 and leading to activation of
specific gene networks in BRCA1-null cells and tumors. A potential
explanation for these findings is the previously recognized
interaction between BRCA1 and elements of the histone
deacetylation complex, including HDAC1 and 2 and the Retino-
blastoma (Rb)-associated proteins RbAp46 and RbAp48.19 This
interaction was mediated by the BRCT domain, which is truncated
in the majority of BRCA1-mutated ovarian and breast tumors,
including in the cellular models used in the current study,
suggesting that the BRCT domain may be indirectly implicated in
protein–protein interactions leading to chromatin remodeling and
Fig. 4 Cellular responses to IFN-γ depend upon BRCA1 mutational status. a Expression levels (means ± s.e.m., n= 3) of the CXCL10, CXCL11,
and IFI16 genes measured by qRT-PCR in HCC1937 (BRCA1-null) and HCC1937+ BRCA1 breast cancer (BC) cells treated with IFN-γ for 24 h. *P <
0.05 (t-test) relative to control (0 h) or between cell lines as indicated. b CXCL10, CXCL11, and IFI16 mRNA expression levels in BRCA1-normal
compared with BRCA1-mutated immortalized mammary epithelial cells. *P < 0.05 (mean ± s.e.m. of three independent measurements in two
BRCA1-normal and one BRCA1-mutated cell cultures, t-test). c–f Cell survival (mean ± SE, n= 4) measured by the CCK8 assay of BRCA1-null and
BRCA1+ ovarian cancer (OC) or BC cells treated with IFN-γ (c, d) or with IFN-α (e, f) for 96 h. *P < 0.05 (t-test) between groups at the indicated
doses. g STAT1 mRNA levels (means ± s.e.m., n= 2) measured by qRT-PCR in BRCA1+ and BRCA1-null UWB1.289 OC cells transduced with a
non-targeting shRNA (shControl) or two different shRNAs directed at STAT1. h CCK8 assay measured proliferation of BRCA1+ and BRCA1-null
UWB1.289 OC cells transduced with shControl or shRNAs targeting STAT1. NS not different (P > 0.05, t-test). Values are percentage of cells
(means ± s.e.m., n= 4) relative to day 1. Shown are t-test P values. i Effects of entinostat (Ent, 0.5 μM), IFN-γ (10 ng/mL), or combination
treatment for 24 h on mRNA expression levels (means ± s.e.m., n= 3) of the CXCL10, CXCL11, and IFI16 genes in BRCA1+ and BRCA1-null
UWB1.289 OC cells. *P < 0.05 (t-test) relative to Control or between BRCA1+ treated with IFN-γ vs. Ent+ IFN-γ for IFI16.
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transcription regulation. In support of this concept, co-recruitment
of BRCA1 and HDAC to the promoter of target genes has been
documented for progesterone receptor (PR) target genes, BRCA1
acting as a repressor by displacing the coactivator AIB1 and
recruiting the co-repressor HDAC1 at the PR responsive
elements.37 Interestingly, we observed decreased HDAC1 enzy-
matic activity in nuclear extracts from BRCA1-null vs. BRCA1+ cells
in association with differences in acetylated chromatin marks
between the isogenic OC cell lines, corroborating previous
evidence linking BRCA1 and histone deacetylases.
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Secondly, we detected an augmented baseline IFN-γ signature
in BRCA1-mutated cancer and primary epithelial cells and tumors
coupled with decreased cytotoxicity induced by IFN-γ or by STAT1
knockdown. Of the IFN-γ-related genes, IFI16 was upregulated
>150-fold at baseline in BRCA1-mutated cancer cells. We observed
increased H3K9Ac and H3K27Ac peaks at the promoter and
enhancer regions of this gene in BRCA1-mutated OC cells,
supporting its transcriptional activation. IFI16 is a member of the
PYHIN family which comprises a pyrin domain and two DNA-
binding HIN domains. IFI16 was shown to act as an intracellular
sensor for viral DNA, to directly bind and activate the STING
pathway, leading to IFN response.31 It is possible that in conditions
of genomic instability related to the presence of a non-functional
BRCA1, this pathway is activated possibly by the presence of
intracellular DNA, initiating an IFN response.
Interestingly, differential apoptotic response to IFN-γ dependent
on the presence of functional BRCA1 was previously observed in
the HCC1937 isogenic breast cancer model,38 although the
mechanism responsible for this phenomenon was not elucidated.
Similarly, it had been reported that IRF7 expression in response to
IFN-γ was augmented in the presence of functional BRCA1, in a
manner dependent of STAT1 and STAT2,39 consistent with our
observations documenting a blunted response to IFN-γ in BRCA1-
deficient cells. Finally, a direct interaction between the BRCT
domain of BRCA1 and STAT1 has been implicated in induction of
p21 and apoptosis in cancer cells in response to IFNs.40 We did not
identify differences in IFN-γ receptor expression or ligand
secretion between the isogenic cells lines and have attributed
the augmented IFN response to an altered transcriptomic program
linked to redistributed H3 acetylated marks in the presence of
BRCA1 mutations. A recent report showed that treatment with
HDAC and DNA methylation inhibitors triggered an IFN response
in a lung cancer model,41 supporting the hypothesis that
regulation of this pathway is highly dependent on histone
deacetylation. This concept is also supported by our observations
showing that addition of an HDACi significantly increased cellular
responses to IFNs in BRCA1+ cells.
Thirdly, our observations that BRCA1-mutated cells are resistant
to IFN-γ-mediated cytotoxicity and to STAT1 downregulation
could have implications for understanding responses to anti-
tumor immunity in BRCA1-mutated cancers. These results could
suggest that this mechanism may play a role in tumor initiation
and progression related to BRCA1 loss of function, as cancer cells
lacking this TSG could use this mechanism to escape the host’s
anti-tumor immune surveillance mechanisms. Further, these
observations could fuel speculations that BRCA1-null tumors
could be resistant to immune interventions. Interestingly, an
mRNA based IFN-γ signature was found to be predictive of
response to immune checkpoint inhibitors in a panel of cancer
patients treated with pembrolizumab42 and mutations in the JAK/
STAT pathway were linked to resistance to immunotherapy.43
While OC is not highly immunogenic, increased levels of immune
effector cells within the tumor have correlated with better anti-
tumor responses and improved survival.44,45 It had been
speculated that BRCA-deficient tumors may be associated with
a more robust anti-tumor immunity, as suggested by an increased
T cell infiltration compared to tumors harboring intact BRCA1
(refs 46,47) and perhaps by an increased somatic mutation load in
these genomically unstable tumors. Our exploratory transcrip-
tomic analyses using TIMER predicted that dendritic cells and
neutrophils as being differentially present in BRCA1-deficient vs.
BRCA normal ovarian tumors, also supporting the concept that
cellular immune responses are augmented in this setting.
However, these findings have not yet panned out in clinical
trials; in a recent evaluation of avelumab in patients with ovarian
cancer, clinical responses to this anti PD-L1 antibody were
uncommon in both patients with BRCA1/2 mutated or in those
with BRCA1/2 wild-type tumors.48 Additionally, a recent pre-
clinical study using an immune-competent mouse model
harboring BRCA1-mutated tumors reported lack of response to
immune checkpoint inhibition.49 Thus, our results showing that
BRCA1-null cells are less susceptible to the cytotoxic effects of
IFN-γ and STAT1 knock down are hypothesis generating and
could argue that such cells may resist elimination by immune cell-
induced IFNγ response due to an enhanced baseline IFNγ
signature. However, in the tumor microenvironment other
mechanisms may be operative and able to overcome this
pathway. Future analyses of tissue specimens from clinical trials
will be necessary to fully understand sensitivity or resistance to
immune interventions in this context.
Lastly, we show that the combination of high mRNA expression
levels for three IFN-γ target genes (CXCL10, CXCL11 and IFI16)
correlated with overall survival in ovarian tumors from the TCGA
database, pointing to the potential clinical significance of this
pathway in HGSOC. In all, these conclusions led us to propose that
tumor-related BRCA1 mutations are associated with an IFN-γ gene
signature, partly regulated through altered H3 acetylation. Our
results could have broader implications for understanding
nuances of anti-tumor immune responses in BRCA-null tumors.
METHODS
Materials
Entinostat, trichostatin A, and etoposide were from Sigma-Aldrich
(St. Louis, MO), interferon (IFN) α-1a from Cell Signaling Inc. (Danvers,
MA, Cat. No. 8927), and IFN-γ from Gibco (Waltham, MA, Cat. No. PHC4033).
Guadecitabine was provided by Astex Pharmaceuticals Inc. (Pleasanton,
CA), and GSK126 was purchased from Xcess Biosciences Inc. (San
Diego, CA).
Cells
BRCA1-mutated (BRCA1-null) OC cells UWB1.289, UWB1.289 cells trans-
duced with the BRCA1 gene, and the BRCA1-null breast cancer cell line
HCC1937 were obtained from the American Type Culture Collection (ATCC,
Manassas, VA). HCC1937 cells with the BRCA1 gene restored using
transduction techniques were kindly provided by Dr. E. Swisher (University
of Washington, Seattle). UWB1.289 cells were transfected with pcDNA3.1
vector to generate BRCA1-null-vector cells. BRCA1-mutated and BRCA1-
normal (wild type) primary mammary epithelial cell lines immortalized by
human telomerase gene (hTERT) were obtained as previously described.50
The immortalized primary mammary epithelial cell lines were maintained
in low glucose Dulbecco’s modified Eagle’s medium (and F12 media (1:3
ratio) supplemented with 5% fetal bovine serum (FBS), 5 μg/mL human
Fig. 5 Differential histone H3K9 and H3K27 acetylation in ovarian cancer (OC) cells carrying a BRCA1 loss-of-function mutation (BRCA1-null).
a Venn diagrams illustrate numbers of unique and common H3K9ac or H3K27ac peaks in BRCA1-null and BRCA1+ UWB1.289 OC cells
measured by ChIP-seq. b Percent distribution of all H3K9ac or H3K27ac peaks among genomic regions in BRCA1+ and BRCA1-null UWB1.289
OC cells. c Percent distribution among genomic regions of differential H3K9ac or H3K27ac peaks in BRCA1-null vs. BRCA1+ UWB1.289 OC cells.
d Differential H3K27ac peaks (−5000 bp to +5000 bp from the peak center) grouped into four clusters and represented as integrated plots
(top) or a heatmap (bottom) in BRCA1-null vs. BRCA1+ UWB1.289 OC cells. Rows on the heatmap represent H3K27ac peaks. e Venn diagrams
shows numbers of common genes having differential promoter H3K9ac or H3K27ac marks (ChIP-seq, blue) and differential expression
(RNAseq, red) between BRCA1-null and BRCA1+ UWB1.289 OC cells. f Profiles of H3K9ac and H3K27ac peaks in the IFN-γ-regulated gene IFI16
in BRCA1-null vs. BRCA1+ UWB1.289 OC cells. g H3K9ac enrichment (means ± s.e.m., n= 2) measured by ChIP-PCR in the promoters of the
IFN-γ-regulated genes CXCL10, CXCL11, and IFI16 in BRCA1-null and BRCA1+ UWB1.289 OC cell line *P < 0.05 (t-test).
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insulin, 0.4 μg/mL hydrocortisone, 20 ng/mL EGF, and 1%
penicillin–streptomycin solution. UWB1.289 cells were cultured in media
containing 1:1 MEBM (Lonza, Elburn, IL, Cat. No. CC-3151) and RPMI 1640
(ATCC, Cat. No. 30-2001) supplemented with 3% FBS, 1%
penicillin–streptomycin solution, and MEGM Single-Quots (Lonza, Cat.
No. CC-4136). HCC1937 cells were maintained in RPMI 1640 supplemented
with 10% FBS and 1% penicillin–streptomycin solution. All primary cells
and cell lines were cultured at 37 °C, and 5% CO2. UWB1.289 (BRCA1-null),
UWB1.289+ BRCA1, and HCC1937 (BRCA1-null) cells lines were obtained
authenticated and mycoplasma-free from the ATCC in 2017. Cell lines are
tested for mycoplasma contamination in our laboratory, or at IDEXX
Bioresearch (Columbia, MO) approximately every 2 years.
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Fig. 6 IFN-γ signaling in high-grade serous ovarian cancer (HGSOC) tumors. a, b Associations determined by regression analysis between
mRNA levels of CXCL10, CXCL11, or IFI16 with IFN-γ a, and between IFI16 with CXCL10 or CXCL11 b in HGSOC samples from the TCGA database.
c Hierarchical clustering of HGSOC tumor specimens profiled in the TCGA based on CXCL10, CXCL11, and IFI16 mRNA expression levels
identified two groups of patients (samples). Columns correspond to individual tumors. d Disease-free survival analysis for patients profiled in
the TCGA and grouped as having “low” or “high” (relative to their median values) combined expression levels for the IFN-γ-regulated genes
CXCL10, CXCL11, and IFI16. The P value is for Cox proportional hazard regression analysis.
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Chromosome immunoprecipitation (ChIP) and ChIP-sequencing
(ChIP-seq)
Chromatin was prepared using a kit (#17-295, Millipore, Billerica, MA)
following the manufacturer’s protocol. Briefly, chromatin was cross-linked
with 1% formaldehyde at 37 °C for 10min. Cells were treated with SDS lysis
buffer and then sonicated (5 pulses of 10 s each at 30-s intervals) using a
Fisher Scientific Model 100 sonicator set at 3. Protein–chromatin complexes
were immunoprecipitated with ChIP-validated antibodies against H3K9ac
(polyclonal, Cat. No. ab4441 used at 1/40; Abcam, Cambridge, MA), H3K27ac
(polyclonal, Cat. No. ab4729 used at 1/50; Abcam), STAT1 (Cat. No. sc-346
used at 1/50 dilution; Santa Cruz Biotechnologies, Dallas, TX), or IgG
(negative control). Immunoprecipitated complexes were separated with
salmon sperm DNA/protein A agarose slurry, followed by chromatin elution,
cross-link reversal, and DNA purification (QIAquick PCR purification kit;
Qiagen, Germantown, MD). STAT1 localization to regions of the CXCL10,
CXCL11, and IFI16 promoters containing a gamma interferon activation site
(GAS) consensus sequence (TTCN2-4GAA) was determined by qPCR using
primers flanking the GAS-containing regions (Supplementary Table 1). DNA
libraries for H3K9ac and H3K27ac ChIP-seq were prepared and sequenced
at the University of Chicago Genomics Facility, Knapp Center for Biomedical
Discovery (Chicago, IL).
RNA-sequencing (RNA-seq)
Total RNA was extracted with the RNA Stat-60 reagent (Tel-Test, Inc.,
Friendswood, TX). Poly(A) mRNA was isolated using a NEBNext Poly(A)
mRNA Magnetic Isolation Module (#7490 S, New England Biolabs Inc.,
Ipswich, MA) following the manufacturer’s protocols. cDNA libraries were
prepared with a NEBNext® mRNA Library Prep Master Mix Set for Illumina
(#E6110S; New England Biolabs Inc.), as previously described,51 and
sequenced at the University of Chicago Genomics Facility, Knapp Center
for Biomedical Discovery (Chicago, IL) using a HiSeq instrument (Illumina,
Wheeling, IL). Data were deposited in Geo (Accession Number GSE131142).
Real-time quantitative RT-PCR (qRT-PCR)
An iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA) was used
for reverse transcription, and iTaq Universal SYBR Green Supermix (Bio-
Rad) was used for quantitative PCR (qPCR) amplification of cDNAs
following the manufacturer’s procedures. Relative changes in amounts of
mRNAs were calculated by the 2−ΔΔCT method using GAPDH for
normalization, as previously described.52 All experiments were repeated
independently at least three times. Regular PCR was performed using
GoTaq Green master mix (Promega, Madison, WI). PCR products were
resolved by agarose gel electrophoresis and digital pictures of gels were
obtained using an image analyzer (ImageQuant LAS 4000; GE Healthcare
Life Sciences, Piscataway, NJ). The sequences of primers used for qRT-PCR
are presented in Supplementary Table 1. Human Interferons and Receptors
RT² Profiler PCR arrays were purchased from Qiagen (Cat. No. PAHS-064Z)
and used with an ABI Prism 7900 HT Real-Time PCR system (Applied
Biosystems, Foster City, CA), as previously described.52
Western blotting
Proteins were resolved by SDS-PAGE and electroblotted onto polyvinyli-
dene difluoride membranes (Millipore). Membranes were blocked and
then probed with antibodies against the proteins of interest. Antibodies
against H3K9ac (polyclonal, Cat. No. ab4441, used at 1/500), H3K27ac
(polyclonal, Cat. No. ab4729, used at 1/1000), and histone H3 (polyclonal,
Cat. No. ab1791, used at 1/1000) were from Abcam Inc.; anti-STAT1 (Cat.
No. sc-346, clone E-23, lot #K1115, used at 1/200) and anti-BRCA1 (Cat. No.
sc-6954, clone D-9, used at 1/250) were from Santa Cruz Biotechnologies;
anti-phospho-STAT1 (Tyr701) (Cat. No. 7649, clone DA47, Lot 5, used at 1/
1000), anti-HDAC1 (Cat. No. 5356, clone 10E2, used at 1/1000), and anti-
phospho-H2AX (γH2AX, Cat. No. 9718, clone 20E3, used at 1/1000) were
from Cell Signaling Technology; anti-β-actin (Cat. No. A1978, clone AC-15,
used at 1/2000) was from Sigma-Aldrich; and anti-GAPDH (Cat. No.
H86504M, clone B2534M, lot # 22012014, used at 1/10,000) was from
Meridian Life Sciences, Inc. (Memphis, TN). Membranes were incubated
with HRP-conjugated secondary antibody, followed by detection of
antigen–antibody complexes using an enhanced chemiluminescent
substrate (SuperSignal West Pico PLUS; Thermo Scientific, Waltham, MA)
and a luminescent image analyzer (ImageQuant LAS 4000; GE Healthcare
Life Sciences, Piscataway, NJ). Detection of additional proteins on the blots
(e.g. total histone H3, Fig. 1; or STAT1 and GAPDH, Fig. 3) was performed
applying the above procedure after treatment with Restore Western Blot
Stripping Buffer (Thermo Scientific). All blots derived from the same
experiment and were processed in parallel. Densitometric analysis of
protein bands used ImageJ 1.48 software (https://imagej.nih.gov/ij). Images
of blots were cropped to show the proteins of interest. Whole images of
representative blots are presented in Supplementary Figs 10–13.
Histone deacetylase activity
Cell lysates were obtained using RIPA buffer. Nuclear proteins were extracted
with an EpiQuik Nuclear Extraction kit (EpigenTek, Farmingdale, NY)
following the manufacturer’s instructions. Total HDAC activity in cell lysates
or nuclear extracts was determined using a HDAC Activity Colorimetric Assay
kit (EpigenTek). Absorbance was measured by an EL800 microplate reader
controlled by Gen5 version 2.09 software (BioTek Instruments, Inc., Winooski,
VT). HDAC activity was expressed as OD/mg of protein.
Cell proliferation assay
The Cell Counting Kit-8 assay (CCK8, Dojindo Molecular Technologies, Inc.,
Rockville, MD) was used to measure cell proliferation following the
manufacturer’s protocol. Absorbance at 450 nm was determined by an
EL800 microplate reader and Gen5 version 2.09 software (BioTek
Instruments, Inc., Winooski, VT).
Immunofluorescence
Cells were grown in eight-well culture slides (Millicell EZ slide, Millipore)
at the density of 20,000 per well. Cells were fixed with 4%
paraformaldehyde for 30 min, and then blocked and permeabilized for
60 min with PBS containing 5% normal goat serum and 0.3% Triton X-
100. Cells were incubated with primary antibody (anti-phospho-H2AX,
Cat. No. 9718, clone 20E3, Cell Signaling, used at 1/200 dilution)
overnight at 4 °C, and then with Alexa Fluor 488-labeled anti-rabbit IgG
(Cat. No. A11008 used at 1/500, Molecular Probes, Eugene, Texas). Slides
were coverslipped using Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA). Digital pictures of stained cells
were obtained using an AxioCam HRC camera attached to an
AxioVert200 inverted microscope and Axiovision release 4.5 software
(Carl Zeiss Microscopy, White Plains, NY).
Cell transfection and transduction
Stable knock-down of STAT1 was performed by RNA interference using
small hairpin RNAs (shRNAs). Lentiviral particles containing shRNAs
targeting STAT1 or control shRNAs were obtained from Sigma-Aldrich
(MISSION TRCN0000280024 and TRCN0000004264). Transduced cells were
selected by antibiotic resistance (puromycin, 2 μg/mL). The pcDNA3.1
vector (Addgene, Watertown, MA) was transfected into UWB1.289 cells
using TurboFectin 8 reagent (OriGene, Austin TX), and stably transfected
cells (named BRCA1-null-vector) were selected with G418 (600 μg/mL).
Statistical analysis
RNAseq data were aligned to assembly HG19 with Tophat 2.53 Quality
control and gene quantification were conducted with NGSUtils,54 and
differential expression analysis was done with Bioconductor edgeR
package in R. Mutation data and clinical data for HGSOC were
downloaded from the TCGA portal (version 02/11/2016). The gene
expression data were obtained on a custom gene expression microarray
Agilent G4502A, and normalized level 3 data were downloaded. Four
exome sequence datasets (BCM SOLiD; BI IlluminaGA; WUSM IlluminaGA;
WUSM IlluminaHiSeq) were downloaded from TCGA portal,1 and
19 samples were identified as carriers of BRCA1 mutations in at least
one of the exome datasets. Samples were then classified as BRCA1-
deficient or BRCA1-normal controls based on gene expression level of
BRCA1 and BRCA1 mutations profile in the exome regions. From a total of
589 samples, 75 samples were considered BRCA-deficient, including
56 samples with expression levels of BRCA1 lower than the 10% quantile
and 19 samples containing somatic mutations in the BRCA1 exome
regions. Three hundred and thirty-one specimens were considered
BRCA1-normal as BRCA1 expression levels exceeded the first quartile and
no somatic mutations were observed in the exonic regions of BRCA1 or
BRCA2 genes. Samples not included within one of these two groups were
removed from further analyses. Analysis of differential gene expression
between the BRCA1-deficient and BRCA1-normal groups was conducted
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with Student’s t-test in statistical environment R, and Benjamini &
Hochberg False Discovery Rate (FDR) was used to adjust for multiple
comparisons. FDR < 0.05 was considered significant.
ChIP-sequencing reads were aligned to the human reference genome
(GRCh38) using Bowtie version 1.2.2 with options-best -m1.55 Subsequent
analyses including peak calling, peak merging, and differential peak
analysis were performed with HOMER version 4.10 (http://homer.ucsd.edu/
homer/) as described below. Alignment files were first converted to
HOMER compatible tag directories using command makeTagDirectory with
option -tbp 1 to ignore duplicate reads. Peaks were called relative to their
respective inputs using HOMER’s findPeaks program with default settings
and option -style histone. Consensus peak lists for each histone
modification ChIP-seq were created using HOMER’s mergePeaks com-
mand. These merged peaks sets were subsequently analyzed for
differential H3K27Ac or H3K9Ac tag density in BRCA1-null versus BRCA1+
cells using HOMER’s getDifferentialPeaks command with fold change cutoffs
of two-fold and Poisson enrichment P value < 0.0001 (default). Location of
H3K27Ac or H3K9Ac peaks relative to genomic regions of interest (i.e.
promoter, intron, exon, TSS) and distance to nearset transcription start site
was determined using HOMER’s annotatePeaks command. Heatmap
visualizations and read per genome coverage normalized bigwig files
were generated in deepTools2 version 3.1; bigwig files were visualized
using IGV (http://broadinstitute.org/igv).
Co-expression among the genes CXCL10, CXCL11, IFI16, and IFNG was
estimated by linear regression using the R software, and a P value < 0.05
was considered statistically significant. We transformed the dependent
variables in our regression models and fit the regression with transformed
dependent variables. We conducted a cubic root transformation to the
expression level of gene IFNG, and fitted the regression model on the
transformed IFNG on CXCL10, CXCL11, and IFI16. We verified the
homoscedasticity assumption with Breusch-Pagan (BP) test for the new
regression.
The Kaplan–Meier method was used to estimate the probabilities for
overall survival and disease-free survival, and the univariate Cox
Proportional Hazard regression model was used to compare survival
differences between subgroups. A summary of the information pertaining
to Reporting Recommendations for Tumor Marker Prognostic Studies
(REMARK) is presented in Supplementary Table 2. Tumor Immune
Estimation Resource (TIMER) was used to estimate the proportion of
immune cells subsets infiltration in BRCA1-deficient and BRCA1-normal
tumor subgroups.34 Gene expression data obtained by RT-PCR, and cell
survival, were analyzed using the Student’s t-test (two-sided) available on
Excel 2013 for Microsoft Windows. Measurements were taken from distinct
samples and averaged within experimental groups. RT-PCR measurements
per sample were the average of three determinations.
DATA AVAILABILITY
RNA-seq and ChIP-seq datasets generated in this study are available at the Gene
Expression Omnibus (GEO) database, National Center for Biotechnology Information
(Super-Series Accession # GSE131142, https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc= GSE131142). The figures associated to these data are Fig. 1d–f, Fig. 5a–f,
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